Samsung Biologics Signs Addl Development And Manufacturing Deal With STCube

(RTTNews) - Samsung Biologics said that it has further expanded its partnership with STCube through an additional development and manufacturing service agreement of STM418, an anti-PD1 immuno-oncology candidate.

Through preliminary studies, STCube reported that STM418, which selectively masks glycosylation site N58 on PD-1, potently inhibits PD-1/PD-L1 binding to enhance anti-tumor immunity.

As per the development and manufacturing agreement, Samsung Biologics will offer full scope of CDO services from cell line development, process development, non-clinical & clinical material manufacturing, to IND submission for global clinical trials of STM418.